These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12449082)

  • 21. The placebo effect in neurological disorders.
    de la Fuente-Fernández R; Schulzer M; Stoessl AJ
    Lancet Neurol; 2002 Jun; 1(2):85-91. PubMed ID: 12849512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual differences in reward responding explain placebo-induced expectations and effects.
    Scott DJ; Stohler CS; Egnatuk CM; Wang H; Koeppe RA; Zubieta JK
    Neuron; 2007 Jul; 55(2):325-36. PubMed ID: 17640532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the placebo effect: contributions from neuroimaging.
    Lidstone SC; Stoessl AJ
    Mol Imaging Biol; 2007; 9(4):176-85. PubMed ID: 17334853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subsecond dopamine fluctuations in human striatum encode superposed error signals about actual and counterfactual reward.
    Kishida KT; Saez I; Lohrenz T; Witcher MR; Laxton AW; Tatter SB; White JP; Ellis TL; Phillips PE; Montague PR
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):200-5. PubMed ID: 26598677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Would the elderly be better off if they were given more placebos?
    Cherniack EP
    Geriatr Gerontol Int; 2010 Apr; 10(2):131-7. PubMed ID: 20100289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BOLD and its connection to dopamine release in human striatum: a cross-cohort comparison.
    Lohrenz T; Kishida KT; Montague PR
    Philos Trans R Soc Lond B Biol Sci; 2016 Oct; 371(1705):. PubMed ID: 27574306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.
    Loiodice S; McGhan P; Gryshkova V; Fleurance R; Dardou D; Hafidi A; Nogueira da Costa A; Durif F
    J Psychopharmacol; 2017 Oct; 31(10):1323-1333. PubMed ID: 28631520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine and serotonin metabolism associated with morphine reward and its inhibition with buspirone: A study in the rat striatum.
    Haleem DJ; Nawaz S; Salman T
    Pharmacol Biochem Behav; 2018 Jul; 170():71-78. PubMed ID: 29782941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Quattrone A; Barbagallo G; Cerasa A; Stoessl AJ
    Mov Disord; 2018 Aug; 33(8):1213-1227. PubMed ID: 30230624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging.
    Ray N; Strafella AP
    Clin EEG Neurosci; 2010 Apr; 41(2):87-93. PubMed ID: 20521491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroimaging study of placebo analgesia in humans.
    Qiu YH; Wu XY; Xu H; Sackett D
    Neurosci Bull; 2009 Oct; 25(5):277-82. PubMed ID: 19784082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling.
    Wenzel JM; Cheer JF
    Neuropsychopharmacology; 2018 Jan; 43(1):103-115. PubMed ID: 28653666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects.
    Volkow ND; Wang GJ; Ma Y; Fowler JS; Wong C; Jayne M; Telang F; Swanson JM
    Neuroimage; 2006 Oct; 32(4):1782-92. PubMed ID: 16757181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reward Prediction Errors in Drug Addiction and Parkinson's Disease: from Neurophysiology to Neuroimaging.
    García-García I; Zeighami Y; Dagher A
    Curr Neurol Neurosci Rep; 2017 Jun; 17(6):46. PubMed ID: 28417291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries.
    Fricchione G; Stefano GB
    Med Sci Monit; 2005 May; 11(5):MS54-65. PubMed ID: 15874901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug addiction. Part II. Neurobiology of addiction.
    Vetulani J
    Pol J Pharmacol; 2001; 53(4):303-17. PubMed ID: 11990077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-lasting contribution of dopamine in the nucleus accumbens core, but not dorsal lateral striatum, to sign-tracking.
    Fraser KM; Janak PH
    Eur J Neurosci; 2017 Aug; 46(4):2047-2055. PubMed ID: 28699296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical aspects of Parkinson's disease.
    Hornykiewicz O
    Neurology; 1998 Aug; 51(2 Suppl 2):S2-9. PubMed ID: 9711973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
    Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.
    Kish SJ; Shannak K; Hornykiewicz O
    N Engl J Med; 1988 Apr; 318(14):876-80. PubMed ID: 3352672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.